Searchable abstracts of presentations at key conferences in endocrinology

ea0098p11 | Population Science | NANETS2023

Sex differences during hospital stay among patients with neuroendocrine neoplasms

Ying Tan Wan , Cramer Laura D. , Vijayvergia Namrata , Lustberg Maryam , Kunz Pamela L.

Background: On the basis of prior large epidemiologic and retrospective studies on treatment-related side effects, it appears that there are sex-based differences in the epidemiology of NENs and treatment-related side effects. The purpose of this study was to examine sex differences in incidence, diagnoses present during hospital stay, and mortality among patients with NENs.Methods: The NIS database was used to define an unweighted sample of patients wit...

ea0098t1 | Trials In Progress | NANETS2023

ACTION-1: A randomized Phase Ib/3 trial of RYZ101 compared with SoC in SSTR+ well-differentiated GEP-NET with progression following Lu-177 SSA

Hope Thomas A. , Halperin Daniel , Strosberg Jonathan , Jacene Heather , E.T. Tesselaar Margot , Kunz Pamela L. , Ferreira Denis , Li Joanne , Ma Kimberly , Rearden Jessica , Moran Susan , Singh Simron

Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by high-density expression of somatostatin receptors (SSTRs), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (225Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR+ solid tumors. Alpha-particles (such as those emitted by 225<...

ea0098c30 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Novel alternate (Alt) response criteria for early outcome prediction in pancreatic (P) neuroendocrine tumors (NETs): utilizing banked imaging and radiomics

Lareef Ishara , Vijayvergia Namrata , Handorf Elizabeth , Kunz Pamela L. , Alkim Emil , Burke Lauren M. , Catalano Paul , Graham Noah , Levin Laura , Li Weier , Meeker Caitlin , Rubin Daniel , Sridharan Anush , O'Dwyer Peter J. , Wong Terence Z. , Anaokar Jordan

Background: Evaluating treatment (Tx) Response in NETs using CT/MRI scans can be difficult. Previous studies, including the E2211, have shown improved progression-free survival (PFS) but no significant difference in Rp as measured by RECIST 1.1 (R1.1) criteria. Therefore, it is difficult to determine Tx effectiveness with short-term imaging, further complicated by differences in imaging protocols and inter-reader variability. Incorporating tumor density, using smaller threshol...